Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Daniel H. Ahn

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0161-4018; OpenAlex author ID A5064791048. Sources: OpenAlex.

Their work

Papers
16 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
60
Papers, trials and grants by year

2015: 3 papers · 2016: 2 papers · 2017: 3 papers · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 3 papers · 2022: none · 2023: 1 paper · 2024: 1 paper

Papers 16

  1. Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers16101861↗
  2. Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail. Co-author DOI 10.5306/wjco.v14.i8.285↗
  3. Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1002/onco.13717↗
  4. Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study. Co-author DOI 10.14309/ctg.0000000000000414↗
  5. Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival. Co-author DOI 10.3389/fonc.2021.794009↗
  6. Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. Last author DOI 10.1097/mpa.0000000000001479↗
  7. Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. Co-author DOI 10.1016/j.pan.2018.11.002↗
  8. Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers10060193↗
  9. Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis. Co-author DOI 10.1002/cncr.30927↗
  10. A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective an… Co-author DOI 10.1177/1758834016676011↗
  11. Targeting the stroma in pancreatic cancer. Co-author DOI 10.21037/cco.2017.11.02↗
  12. Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1038/mt.2016.66↗
  13. Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-15-1732↗
  14. Retrotransposon insertions in the clonal evolution of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/nm.3919↗
  15. Immunological predictors of overall survival in treatment naïve metastatic pancreatic cancer patients Co-author DOI 10.1186/2051-1426-3-s2-p85↗
  16. Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value. Co-author DOI 10.14694/edbook_am.2015.35.e222↗

Closest collaborators

The 25 strongest of 60 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tanios Bekaii‐Saab · 14 shared papers, 2015–2024 · strength 1.31
  2. Mitesh J. Borad · 5 shared papers, 2017–2023 · strength 0.55
  3. Mohamad Bassam Sonbol · 5 shared papers, 2017–2023 · strength 0.55
  4. Jason Scott Starr · 3 shared papers, 2021–2023 · strength 0.37
  5. Ramesh K. Ramanathan · 3 shared papers, 2017–2018 · strength 0.35
  6. Hani M. Babiker · 2 shared papers, 2023–2024 · strength 0.33
  7. Pedro Luiz Serrano Usón · 3 shared papers, 2021 · strength 0.32
  8. Christina Sing-Ying Wu · 4 shared papers, 2015–2023 · strength 0.30
  9. Anne M. Noonan · 5 shared papers, 2015–2019 · strength 0.28
  10. Umair Majeed · 2 shared papers, 2021–2023 · strength 0.27
  11. Matthew R. Farren · 4 shared papers, 2015–2019 · strength 0.22
  12. Thomas A. Mace · 4 shared papers, 2015–2019 · strength 0.22
  13. Gregory B. Lesinski · 4 shared papers, 2015–2019 · strength 0.22
  14. Gehan Botrus · 2 shared papers, 2021 · strength 0.21
  15. Kabir Mody · 2 shared papers, 2021 · strength 0.21
  16. Alexander Revzin · 1 shared paper, 2024 · strength 0.17
  17. Thorvardur Ragnar Halfdanarson · 1 shared paper, 2024 · strength 0.17
  18. Sani Haider Kizilbash · 1 shared paper, 2024 · strength 0.17
  19. Aakash P. Desai · 1 shared paper, 2024 · strength 0.17
  20. Alex A. Adjei · 1 shared paper, 2024 · strength 0.17
  21. Daheui Choi · 1 shared paper, 2024 · strength 0.17
  22. Aaron Scott Mansfield · 1 shared paper, 2024 · strength 0.17
  23. Steven R. Alberts · 1 shared paper, 2024 · strength 0.17
  24. Ryan Michael Carr · 1 shared paper, 2024 · strength 0.17
  25. Wen Wee Ma · 1 shared paper, 2024 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.